Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Case-Based Peer Perspectives: A 65-Year-Old Man Diagnosed with PSMA-positive mCRPC

PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

Videos

Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy, docetaxel, cabazitaxel, and enzalutamide before ultimately being evaluated for Lutetium-177 therapy based on PSMA PET imaging and trial data.

Neal Shore, MD, FACS, discusses the progress of a 65-year-old patient with  mCRPC through various treatments and evaluation for Lutetium-177 therapy based on his PSMA PET scan and MRI.

Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.

Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

Neal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.

Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.

Treatment Considerations for PSMA-Positive mCRPC Patients

Case Based Peer Perspectives

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP: 1.Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

EP: 2.PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP: 3.Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

EP: 4.Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

EP: 5.Treatment Considerations for PSMA-Positive mCRPC Patients